Wave Life Sciences Ltd. - Ordinary Shares (WVE)

Oncotelic Therapeutics (OTCQB: OTLC) is emerging as a key example of how scientific progress is increasingly being reflected as measurable financial value across the biotechnology sector, supported by evolving fair-value accounting practices under U.S. GAAP. Operating at the intersection of oncology and AI-driven drug development, the company highlights this shift through its diversified pipeline and strategic holdings, including a 45% stake in GMP Bio valued at over $1 billion, alongside peers such as Autolus Therapeutics plc (NASDAQ: AUTL), Wave Life Sciences Ltd. (NASDAQ: WVE), IO Biotech Inc. (OTC: IOBTQ), and Roche Holding AG (OTC: RHHBY), as the industry transitions toward valuing clinical progress as an asset class.

BioMedWire Editorial Coverage: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is supported by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to incorporate clinical progress, probability of success and expected commercialization timelines into measurable balance sheet value. Companies at the forefront of this shift, including Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ), are actively leveraging this evolving framework. Operating at the intersection of oncology therapeutics and AI-driven drug development, Oncotelic demonstrates how scientific advancement can influence financial positioning. Through a diversified pipeline and strategic holdings, including a 45% interest in GMP Bio, which was recently assessed at more than $1 billion in enterprise value, the company illustrates how innovation can be reflected in tangible economic terms. As the industry increasingly aligns valuation with development progress rather than current revenue, Oncotelic represents a compelling example of science emerging as a recognized asset class. The company is part of a broader group of organizations developing advanced therapies at the genetic and molecular level, including Autolus Therapeutics plc (NASDAQ: AUTL), Wave Life Sciences Ltd. (NASDAQ: WVE), IO Biotech Inc. (NASDAQ: IOBTQ) and…

CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, April 28, 2026, to review the company’s first quarter 2026 financial results and provide business updates.

AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is supported by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to incorporate clinical progress, probability of success and expected commercialization timelines into measurable balance sheet value. Companies at the forefront of this shift, including Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), are actively leveraging this evolving framework. Operating at the intersection of oncology therapeutics and AI-driven drug development, Oncotelic demonstrates how scientific advancement can influence financial positioning. Through a diversified pipeline and strategic holdings, including a 45% interest in GMP Bio, which was recently assessed at more than $1 billion in enterprise value, the company illustrates how innovation can be reflected in tangible economic terms. As the industry increasingly aligns valuation with development progress rather than current revenue, Oncotelic represents a compelling example of science emerging as a recognized asset class. The company is part of a broader group of organizations developing advanced therapies at the genetic and molecular level, including Autolus Therapeutics plc (NASDAQ: AUTL), Wave Life Sciences Ltd. (NASDAQ: WVE), IO Biotech Inc. (OTC: IOBTQ) and Roche Holding AG (OTC: RHHBY).

CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, is seeking shareholders’ and Singapore High Court approvals in relation to a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Scheme of Arrangement”), in order to redomicile the parent company of the Wave Life Sciences group of companies from Singapore to the United States (the “Redomiciliation”).

CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that its board of directors has unanimously approved a plan to redomicile the parent company of the Wave Life Sciences group of companies from Singapore to the United States (the Redomiciliation).

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p<0.05) and total fat (-5%), stabilization of lean mass (+2%), and reductions in waist circumference (-3%) and body weight (-1%)

Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference

On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while preserving muscle mass

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET.

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026, to review the company’s fourth quarter and full year 2025 financial results and provide business updates.

WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies address both lung and liver manifestations of this disease

AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology mergers and acquisitions (M&As) are increasingly shaped by a clear strategic evolution. Pharmaceutical companies are prioritizing clinical-stage and late-stage programs supported by human data rather than early discovery platforms with uncertain timelines. Following a period where capital heavily favored preclinical innovation, investors and acquirers are now focusing on assets that demonstrate safety signals, efficacy data and clearer pathways toward commercialization. Within this shifting landscape, companies holding diversified clinical-stage portfolios across oncology and central nervous system (CNS) indications are drawing renewed attention. One such example is Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), which recently announced expanded international intellectual property coverage for OT-101, its proprietary TGF-β antisense therapeutic platform. The development strengthens protection across neurology, oncology and CNS drug-delivery technologies aimed at crossing the blood–brain barrier. This evolving M&A environment highlights Oncotelic’s positioning within oncology and CNS innovation alongside industry leaders such as Denali Therapeutics Inc. (NASDAQ: DNLI), Roche Holdings AG (OTCMKTS: RHHBY), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) and Wave Life Sciences Ltd. (NASDAQ: WVE).

Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026, and initiate new trials of WVE-007 as an add-on to incretin and as post-incretin maintenance in 2026

CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 13, 2026 at 2:15 p.m. PT / 5:15 p.m. ET.

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), announced today the pricing of its previously announced underwritten public offering of 15,789,475 of its ordinary shares at a price to the public of $19.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 2,631,578 ordinary shares at an offering price of $18.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant.

ENDRA Life Sciences (NASDAQ: NDRA) is redefining how emerging health-tech companies accelerate breakthrough innovation while maintaining disciplined capital efficiency. The developer of TAEUS® (Thermo-Acoustic Enhanced UltraSound) has implemented a modern treasury strategy managed by Arca Investment Management, converting idle cash into a structured, yield-generating engine that supports long-term growth without shareholder dilution.

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), announced today that it has commenced an underwritten public offering of $250 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and shares underlying pre-funded warrants sold in the public offering on the same terms and conditions. All of the securities in the offering will be sold by Wave Life Sciences.

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07), and a 3.2% increase in lean mass (4.0 lbs; p=0.01), with no statistically significant changes in the placebo group

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will announce interim data from the ongoing Phase 1 INLIGHT clinical trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave’s proprietary SpiNA design, for the treatment of obesity on Monday, December 8, 2025. A press release announcing the interim data will be issued at 7:30 a.m. ET, followed by an investor conference call and webcast at 8:30 a.m. ET.

WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding levels that led to weight loss and prevention of rebound weight gain following cessation of GLP-1 in preclinical models 

CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave’s management team are scheduled to participate in two upcoming investor conferences in November.

Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving muscle mass with once or twice annual dosing

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Monday, November 10, 2025, to review the company’s third quarter 2025 financial results and provide business updates.

This press release corrects and replaces the company’s press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical error in the first sub-bullet under “WVE-007 (GalNAc-siRNA)” – “Next steps.”